

Atty Dkt. No.: CELL-017

USSN: 09/814,357

The Commissioner is hereby authorized to charge any other fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number CELL-017.

Respectfully submitted,

Date: August 14, 2002By: Pamela J. Sherwood
Pamela J. Sherwood, Ph.D.
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

BEST AVAILABLE COPY

Atty Dkt. No.: CELL-017

USSN: 09/814,357

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Cancel claims 1-58.

BEST AVAILABLE COPY

Add the following new claims:

59. A method for suppressing tumor growth in an individual comprising: administering a target cell-specific adenovirus vector, said vector comprising an adenoviral early gene essential for replication under transcriptional control of a target cell-specific transcriptional regulatory element (TRE), selected from the group consisting of a prostate-specific antigen (PSA)-TRE, an α -fetoprotein (AFP)-TRE and a human uroplakin II (UPII)-TRE and at least one antineoplastic agent selected from the group consisting of paclitaxel, docetaxel, doxorubicin and cisplatin, wherein the amount of antineoplastic agent administered is less than that known in the art to be effective for suppressing tumor growth when administered alone

60. The method of claim 59, wherein said at least one antineoplastic agent is doxorubicin.

61. The method of claim 59, wherein said at least one antineoplastic agent is cisplatin.

62. A method for suppressing tumor growth in an individual comprising: administering a target cell-specific adenovirus vector, said vector comprising an adenoviral gene essential for replication under transcriptional control of a prostate-specific antigen (PSA)-TRE and at least one antineoplastic agent selected from the group consisting of etoposide, estramustin and 5-fluorouracil (5-FU), wherein the amount of antineoplastic agent administered is less than that known in the art to be effective for suppressing tumor growth when administered alone.

63. The method of claim 59, wherein said at least one antineoplastic agent is selected from the group consisting of paclitaxel, docetaxel and etoposide.

64. The method of claim 59, wherein said at least one antineoplastic agent is 5-fluorouracil (5-FU).

65. The method of claim 59, wherein said at least one antineoplastic agent is doxorubicin or mitoxantrone.

66. The method of claim 59, wherein said at least one antineoplastic agent is estramustine or cisplatin.

Atty Dkt. No.: CELL-017

USSN: 09/814,357

67. A method for suppressing tumor growth in an individual comprising: administering a target cell-specific adenovirus vector, said vector comprising an adenoviral gene essential for replication under transcriptional control of an α -fetoprotein (AFP)-TRE and at least one antineoplastic agent selected from the group consisting of paclitaxel, docetaxel, doxorubicin, cisplatin, mitomycin C, and mitoxantrone, wherein the amount of antineoplastic agent administered is less than that known in the art to be effective for suppressing tumor growth when administered alone.

68. The method of claim 67, wherein said at least one antineoplastic agent is paclitaxel or docetaxel.

69. A method for suppressing tumor growth in an individual comprising: administering a target cell-specific adenovirus vector, said vector comprising an adenoviral gene essential for replication under transcriptional control of a human uroplakin II (UPII) transcriptional regulatory element (TRE), and at least one antineoplastic agent selected from the group consisting of paclitaxel, docetaxel, doxorubicin and cisplatin, wherein the amount of antineoplastic agent administered is less than that known in the art to be effective for suppressing tumor growth when administered alone.

70. The method of claim 69, wherein said at least one antineoplastic agent is paclitaxel or docetaxel.

71. A method for suppressing tumor growth in an individual comprising: administering a target cell-specific adenovirus vector, said vector comprising an adenoviral gene essential for replication under transcriptional control of a prostate-specific antigen (PSA)-TRE or an α -fetoprotein (AFP)-TRE, together with mitoxantrone, wherein the amount of mitoxantrone administered is less than that known in the art to be effective for suppressing tumor growth when administered alone.

72. The method of claim 59, wherein the adenoviral early gene is E1A.

73. The method of claim 59, wherein the adenoviral early gene is E1B.

74. The method of claim 73, wherein E1B has a deletion of the 19-kDa region.

75. A method for suppressing tumor growth in an individual comprising: administering a target cell-specific adenovirus vector, said vector comprising an adenoviral gene essential for replication under transcriptional control of a target cell-specific transcriptional regulatory element (TRE), selected from the

BEST AVAILABLE COPY

Atty Dkt. No.: CELL-017

USSN: 09/814,357

group consisting of a prostate-specific antigen (PSA)-TRE, an α -fetoprotein (AFP)-TRE and a human uroplakin II (UPII)-TRE and administering an effective amount of an appropriate course of external radiation therapy to the individual wherein the amount of radiation administered is less than that known in the art to be effective for suppressing tumor growth when administered alone.

76. The method of claim 77, wherein said TRE is a prostate-specific antigen (PSA)-TRE.

BEST AVAILABLE COPY